bioAffinity Technologies (NASDAQ:BIAF) Releases Earnings Results, Misses Estimates By $0.07 EPS

bioAffinity Technologies (NASDAQ:BIAF) released its quarterly earnings results on Monday. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.07), Zacks reports. bioAffinity Technologies had a negative net margin of 91.22% and a negative return on equity of 205.09%. The company had revenue of $2.20 million for the quarter, compared to the consensus estimate of $2.42 million. bioAffinity Technologies updated its FY 2025 guidance to EPS.

bioAffinity Technologies Trading Up 319.2 %

Shares of NASDAQ BIAF traded up $0.83 during mid-day trading on Tuesday, hitting $1.09. The company’s stock had a trading volume of 488,258,307 shares, compared to its average volume of 2,268,352. bioAffinity Technologies has a one year low of $0.24 and a one year high of $3.16. The company’s fifty day simple moving average is $0.57 and its 200-day simple moving average is $1.07. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.02 and a quick ratio of 1.01. The stock has a market cap of $16.99 million, a price-to-earnings ratio of -1.33 and a beta of 3.12.

Analyst Upgrades and Downgrades

Separately, Maxim Group reissued a “hold” rating on shares of bioAffinity Technologies in a research note on Tuesday.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.